Авторы

  • Axmatova K.A.
  • Sabirova R.A.
  • Azizova D.M.

Ключевые слова:

multifokal ateroskleroz, kalsifikatsiya, proprotein konvertaza subtilizin keksin 9 tip, lipoil kislota, yalligʻlanish, YuIK, ZPLP retseptori.

Библиографические ссылки

Ruparelia N, Chai JT, Fisher EA, Choudhury RP. Inflammatory processes in cardiovascular disease: a route to targeted therapies. Nat Rev Cardiol. (2017) 14:133–44. doi: 10.1038/nrcardio.2016.185

Zhang Y, Zhu CG, Xu RX, Li S, Guo YL, Sun J, et al. Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease. J Clin Lipidol. (2014) 8:494–500. doi: 10.1016/j.jacl.2014.07.001

Xie W, Liu J, Wang W, Wang M, Qi Y, Zhao F, et al. Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: a cohort study. Int J Cardiol. (2016) 215:293–8. doi: 10.1016/j.ijcard.2016.04.103

Pirillo A, Norata GD, Catapano AL. LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm. (2013) 2013:152786. doi: 10.1155/2013/152786

Ferri N, Marchiano S, Tibolla G, Baetta R, Dhyani A, Ruscica M, et al. PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. Atherosclerosis. (2016) 253:214–24.doi: 10.1016/j.atherosclerosis. 2016.07.910

Li S, Guo YL, Xu RX, Zhang Y, Zhu CG, Sun J, et al. Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. Atherosclerosis. (2014) 234:441–5. doi: 10.1016/j.atherosclerosis.2014.04.0 01

Gencer B, Montecucco F, Nanchen D, Carbone F, Klingenberg R, Vuilleumier N, et al. Prognostic value of PCSK9 levels in patients with acute coronary syndromes. Eur Heart J. (2016) 37:546–53. doi: 10.1093/eurheartj/ehv637

Shapiro MD, Fazio S. PCSK9 and atherosclerosis - lipids and beyond. J Atheroscler Thromb. (2017) 24:462–72. doi: 10.5551/jat.RV17003

Sun HL, Wu YR, Song FF, Gan J, Huang LY, Zhang L, et al. Role of PCSK9 in the development of mouse periodontitis before and after treatment: a double edged sword. J Infect Dis. (2018) 217:667–80. doi: 1093/infdis/jix574

Giunzioni I, Tavori H, Covarrubias R, Major AS, Ding L, Zhang Y, et al. Local effects of human PCSK9 on the atherosclerotic lesion. J Pathol. (2016) 238:52–62. doi: 10.1002/path.4630

Li S, Zhang Y, Xu RX, Guo YL, Zhu CG, Wu NQ, et al. Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease. Ann Med. (2015) 47:386–93. doi: 10.3109/ 07853890.2015.1042908

Heinzl MW, Resl M, Klammer C, Egger M, Dieplinger B, Clodi M. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is not induced in artificial human inflammation and is not correlated with inflammatory response. Infect Immun. (2020) 88: piie 00842–19. doi: 10.1128/IAI.00842-19

Tavori H, Giunzioni I, Predazzi IM, Plubell D, Shivinsky A, Miles J, et al. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms. Cardiovasc Res. (2016) 110:268–78. doi: 10.1093/ cvr/cvw053

Sun H, Krauss RM, Chang JT, Teng BB. PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction. J Lipid Res. (2018) 59:207–23. doi: 10.1194/jlr.M0783 60

Kuhnast S, van der Hoorn JW, Pieterman EJ, van den Hoek AM, Sasiela WJ, Gusarova V, et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res. (2014) 55:2103–12. doi: 10.1194/ jlr.M051326

Landlinger C, Pouwer MG, Juno C, van der Hoorn JWA, Pieterman EJ, Jukema JW, et al. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE∗ 3Leiden.CETP mice. Eur Heart J. (2017) 38:2499– 507. doi: 10.1093/eurheartj/ehx260

Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis Hypertension. (2004) 44:6–11. doi: 10.1161/ 01.HYP.0000130484.20501.df

Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. (2010) 375:132–40. doi: 10.1016/S0140-6736(09)61717-7

Pradhan AD, Aday AW, Rose LM, Ridker PM. Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy. Circulation. (2018) 138:141–9. doi: 10.1161/CIRCULATIONAHA. 118.034645

Fernandez-Friera L, Fuster V, Lopez-Melgar B, Oliva B, Sanchez-Gonzalez J, Macias A, et al. Vascular inflammation in subclinical atherosclerosis detected by hybrid PET/MRI. J Am Coll Cardiol. (2019) 73:1371–82. doi: 10.1016/j.jacc.2018.12.075

Hossain E, Ota A, Karnan S, Takahashi M, Mannan SB, Konishi H, et al. Lipopolysaccharide augments the uptake of oxidized LDL by up-regulating lectin-like oxidized LDL receptor-1 in macrophages. Mol Cell Biochem. (2015) 400:29–40. doi: 10.1007/ s11010-014-2259-0

Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. (1997) 272:20963–6. doi: 10.1074/jbc.272. 34.20963

Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int J Cardiol. (2013) 168:5126–34. doi: 10.1016/j.ijcard.2013.07. 113

Dozio E, Ruscica M, Vianello E, Macchi C, Sitzia C, Schmitz G, et al. PCSK9 expression in epicardial adipose tissue: molecular association with local tissue inflammation. Mediators Inflamm. (2020) 2020:1348913. doi: 10.1155/2020/1348913

Ding Z, Liu S, Wang X, Deng X, Fan Y, Shahanawaz J, et al. Crosstalk between LOX-1 and PCSK9 in vascular tissues. Cardiovasc Res. (2015) 107:556–67. doi: 10.1093/cvr/cvv178

Boyd JH, Fjell CD, Russell JA, Sirounis D, Cirstea MS, Walley KR. Increased Plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis. J Innate Immun. (2016) 8:211–20. doi: 10.1159/000442976

Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, Boersma E, van Geuns RJ, Serruys PW, et al. PCSK9 in relation to coronary plaque inflammation: results of the ATHEROREMO-IVUS study. Atherosclerosis. (2016) 248:117– 22. doi: 10.1016/j.atherosclerosis.2016.03.010

Almontashiri NA, Vilmundarson RO, Ghasemzadeh N, Dandona S, Roberts R, Quyyumi AA, et al. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies. PLoS ONE. (2014) 9:e106294. doi: 10.1371/journal.pone.0106294

Kochkarov V.I., Buravleva S.V., Pokrovskii M.V., Pokrovskaya T.G., Gudyrev O.S., Korokin M.V., Grigorenko A.P. Endothelioprotection effects of thioctic acid drugs. Приволжский научный вестник №2 – 2011. 84-88

Marwa S. Al-Nami, Hayder M. Al-Kuraishy, Ali I. Al-Gareeb. Impact of thioctic acid on glycemic indices and associated inflammatory-induced endothelial dysfunction in patients with type 2 diabetes mellitus: A case control study. (2020) International Journal of Critical Illness and Injury Sciense IP:5.62.145.16 http://www.ijciis.org S21-S-27